Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pan-flu multivariant mucosal vaccine
- Development stage
- Preclinical
- Lead developer
- TFF Pharmaceuticals
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Mucosal
01
Overview
The pan-flu multivariant mucosal vaccine is a universal influenza vaccine developed by TFF Pharmaceuticals in collaboration with Dr. Ted Ross's lab at the Cleveland Clinic. It is formulated as a shelf-stable, dry powder using TFF's patented Thin Film Freezing (TFF) technology, eliminating the need for cold-chain storage. This vaccine aims to be over 75% effective against symptomatic influenza and provide protection against both group I and II influenza A viruses, addressing limitations of current seasonal flu vaccines and improving global accessibility.
Beyond the preview
Go deeper on pan-flu multivariant mucosal vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pan-flu multivariant mucosal vaccine.